152732-85-9

Upstream product

• 132235-67-7 (2S,3R)-4-O-benzoyl-1-O-(p-bromobenzyl)-3-(2'-propenyl)-1,2,4-butanetriol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 132235-65-5 (2S,3R)-1-O-(p-bromobenzyl)-3-(2'-propenyl)-1,2,4-butanetriol 
• 108267-97-6 (2S,3R)-4-(p-bromobenzyloxy)-2,3-epoxybutan-1-ol 

Downstream Products

• 152732-86-0 (2S,3R)-4-O-benzoyl-1-O-(4-bromobenzyl)-2-O-tert-butyldimethylsilyl-3-(3-hydroxypropyl)-1,2,4-butanetriol 
• 152732-87-1 (4R,5S)-4-benzoyloxymethyl-6-(4-bromobenzyloxy)-5-tert-butyldimethyl-silyloxy-1-hexanal 
• 152732-92-8 1-(2,3,4-trideoxy-4-C-benzoyloxymethyl-6-O-benzoyl-β-D-erythro-hexopyranosyl)uracil 
• 152732-95-1 9-(6-O-benzoyl-4-C-benzoyloxymethyl-2,3,4-trideoxy-β-D-erythro-hexopyranosyl)-6-chloropurine 

Relevant academic research and scientific papers

Synthesis of 4-C-hydroxymethyl hexopyranosyl nucleosides as potential inhibitors of HIV

The synthesis of 1-(2,3,4-trideoxy-4-C-hydroxymethyl-β-D-erythro-hexopyranosyl)thymine (13); -uracil (15), -cytosine (16) and 9-(2,3,4-trideoxy-4-C-hydroxymethyl-β-D-erythro-hexopyranosyl)adenine (18) are described. The nucleoside analogues were evaluated